High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
Authors:
- 1 October 2014
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 86 (1) , 113-114
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare of Japan (23-A-16)
- Japan Society for the Promotion of Science (23590648)
This publication has 5 references indexed in Scilit:
- Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung CancerClinical Pharmacokinetics, 2013
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug DevelopmentDrug Metabolism and Pharmacokinetics, 2012
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasmaJournal of Chromatography B, 2011
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II StudyJournal of Thoracic Oncology, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005